Ten years of proteomics in multiple sclerosis
The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis, which is the most common cause of chronic neurological disability in young adults, is an inflammatory, demyelinating, and neurodegenerative disease of the CNS, which leads to the formation of multiple foci of demyelinated lesions in the white matter. The diagnosis is based currently on magnetic resonance image and evidence of dissemination in time and space. However, this could be facilitated if biomarkers were available to rule out other disorders with similar symptoms as well as to avoid cerebrospinal fluid analysis, which requires an invasive collection. Additionally, the molecular mechanisms of the disease are not completely elucidated, especially those related to the neurodegenerative aspects of the disease. The identification of biomarker candidates and molecular mechanisms of multiple sclerosis may be approached by proteomics. In the last 10 years, proteomic techniques have been applied in different biological samples ( CNS tissue, cerebrospinal fluid, and blood) from multiple sclerosis patients and in its experimental model. In this review, we summarize these data, presenting their value to the current knowledge of the disease mechanisms, as well as their importance in identifying biomarkers or treatment targets.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Proteomics approach has been widely adopted in studies of human diseases including cancer (Frantzi et al., 2015; S. Pan, Brentnall, & Chen, 2015; Petricoin et al., 2002; Tsai et al., 2015), multiple sclerosis (Farias, Pradella, Schmitt, Santos, & Martins-de-Souza, 2014) and schizophrenia (Al Awam et al., 2015; Nascimento & Martins-de-Souza, 2015).”
From Integrative Analysis of Multi-omics Data for Discovery and Functional Studies of Complex Human Diseases (2016) · cites this paper as Farias et al., 2014
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802 · cited 1×
“Although the latest diagnostic criteria review excludes the analysis of CSF parameters [56, 57], oligoclonal bands (OCBs), which are present in the CSF of a high percentage (∼90%) of multiple sclerosis patients, are the best parameter to confirm the diagnosis [58].”
BackgroundControl of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Regulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325 · cited 1×
“Regulatory T cells play a crucial role in the control of inflammation during EAE development [46–48].”
BackgroundKorn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873 · cited 1×
“However, recent studies have noted the role of Th17 cells in the pathogenesis of EAE and other autoimmune diseases [37–39].”
ResultAnderson, N. L., & Anderson, N. G. (2002) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r200007-mcp200 · Cited by 4,414
Prostaglandins and Inflammation
Ricciotti, E., & FitzGerald, G. A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207449 · Cited by 3,803 · cited 1×
“Prostaglandins are one of the cardinal signs of acute inflammation and play a crucial role in the inflammatory response [70].”
BackgroundCompston, A., & Coles, A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08220-x · Cited by 1,743
Steinman, L. (2007) · Nature Medicine · doi:10.1038/nm1551 · Cited by 1,376 · cited 2×
“Th1 cells express and release proinflammatory cytokines such as IFN- and TNF- in response to IL-12 stimulation [34].”
BackgroundRegulatory T cells exert checks and balances on self tolerance and autoimmunity
Wing, K., & Sakaguchi, S. (2010) · Nature Immunology · doi:10.1038/ni.1818 · Cited by 1,107 · cited 1×
“Regulatory T cells play a crucial role in the control of inflammation during EAE development [46–48].”
BackgroundVitamin D intake and incidence of multiple sclerosis
Munger, K. L., Zhang, S. M., O’Reilly, E., Hernán, M. A., Olek, M. J., Willett, W. C., & Ascherio, A. (2004) · Neurology · doi:10.1212/01.wnl.0000101723.79681.38 · Cited by 1,093
Cited by
Sun, Y. V., & Hu, Y.-J. (2016) · Advances in Genetics · doi:10.1016/bs.adgen.2015.11.004 · Cited by 459
“…sclerosis and schizophrenia have not established any reliable protein biomarkers to classify patients after years of investigation of different biological samples (e.g. CNS tissue, cerebrospinal fluid, peripheral blood, plasma and serum) (Farias et al., 2014; Nascimento & Martins-de-Souza, 2015).”
BackgroundAnoctamin 2 identified as an autoimmune target in multiple sclerosis
Ayoglu, B., Mitsios, N., Kockum, I., Khademi, M., Zandian, A., Sjöberg, R., Forsström, B., Bredenberg, J., Lima Bomfim, I., Holmgren, E., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518553113 · Cited by 111
“One of the main focus areas in MS research is the identification of molecular biomarker candidates, which would facilitate diagnosis and prognostic assessments in MS (9).”
BackgroundProteomics of protein post-translational modifications implicated in neurodegeneration
Ren, R.-J., Dammer, E. B., Wang, G., Seyfried, N. T., & Levey, A. I. (2014) · Translational Neurodegeneration · doi:10.1186/2047-9158-3-23 · Cited by 63
“in tissue, subcellular and biochemical fractions, and biomarkers in the extracellular milieu, including plasma or cerebrospinal fluid (CSF)] with a variety of specific proteomic methods have been involved in successful biomarker discovery, drug target development and elucidation of pathogenic mechanisms in the past 20…”
Myelin: Methods for Purification and Proteome Analysis
Erwig, M. S., Hesse, D., Jung, R. B., Uecker, M., Kusch, K., Tenzer, S., Jahn, O., & Werner, H. B. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9072-6_3 · Cited by 64
Revisiting the Pathoetiology of Multiple Sclerosis: Has the Tail Been Wagging the Mouse?
Sen, M. K., Almuslehi, M. S. M., Shortland, P. J., Coorssen, J. R., & Mahns, D. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.572186 · Cited by 55
Byström, S., Ayoglu, B., Månberg, A., Mitsios, N., Hong, M., Drobin, K., Forsström, B., Fredolini, C., Khademi, M., Amor, S., et al. (2014) · Journal of Proteome Research · doi:10.1021/pr500609e · Cited by 54
Raphael, I., Webb, J., Stuve, O., Haskins, W., & Forsthuber, T. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.991315 · Cited by 51
Multiple Sclerosis Biomarker Discoveries by Proteomics and Metabolomics Approaches
Jafari, A., Babajani, A., & Rezaei–Tavirani, M. (2021) · Biomarker Insights · doi:10.1177/11772719211013352 · Cited by 53
Guldbrandsen, A., Farag, Y. M., Kroksveen, A. C., Oveland, E., Lereim, R. R., Opsahl, J. A., Myhr, K., Berven, F. S., & Barsnes, H. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o116.064477 · Cited by 50
Sen, M. K., Almuslehi, M. S. M., Gyengesi, E., Myers, S. J., Shortland, P. J., Mahns, D. A., & Coorssen, J. R. (2019) · Cells · doi:10.3390/cells8111314 · Cited by 35
Serum proteomics in multiple sclerosis disease progression
Tremlett, H. L., Dai, D. L., Hollander, Z., Kapanen, A. I., Aziz, T., Wilson-McManus, J., Tebbutt, S. J., Borchers, C. H., Oger, J., & Freue, G. V. C. (2015) · Journal of Proteomics · doi:10.1016/j.jprot.2015.02.018 · Cited by 34
“With the ongoing growth of extremely sensitive high throughput proteomics technologies, an alternative approach of emerging interest is the application of mass spectrometric untargeted technologies to conduct a broad, discovery driven, and unbiased identification of disease biomarkers [3-6].”
BackgroundInfluentialSen, M. K., Almuslehi, M. S. M., Shortland, P. J., Mahns, D. A., & Coorssen, J. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147377 · Cited by 34
“Additionally, urine and CSF are also routinely sampled for diagnostic purposes [52,109,155].”
BackgroundEffects of Acupuncture on Gait of Patients with Multiple Sclerosis
Criado, M. B., Santos, M. J., Machado, J. P., Gonçalves, A. M., & Greten, H. J. (2017) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2016.0355 · Cited by 37
Integration of lectin–glycan recognition systems and immune cell networks in CNS inflammation
Méndez‐Huergo, S. P., Maller, S. M., Farez, M., Mariño, K. V., Correale, J. D., & Rabinovich, G. A. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.02.003 · Cited by 28
“In spite of considerable evidence highlighting the contribution of genomics, proteomics and lipidomics to demyelinating disease [59,60], the relevance of glycomics to the pathogenesis of MS is just unfolding.”
Experimental Analysis of Tear Fluid and Its Processing for the Diagnosis of Multiple Sclerosis
Tomečková, V., Tkáčiková, S., Talian, I., Fabriciová, G., Hovan, A., Kondrakhova, D., Zakuťanská, K., Skirková, M., Komanický, V., & Tomašovičová, N. (2023) · Sensors · doi:10.3390/s23115251 · Cited by 21
“The identification of protein biomarkers and molecular mechanisms of MS may be facilitated by proteomics as a promising tool for revealing molecular pathways and quantifying differentially expressed proteins [17,18].”
BackgroundSerum proteomic analysis of a pre‐symptomatic multiple sclerosis cohort
Wallin, M. T., Oh, U., Nyalwidhe, J. O., Semmes, J. O., Kislinger, T., Coffman, P., Kurtzke, J. F., & Jacobson, S. (2014) · European Journal of Neurology · doi:10.1111/ene.12534 · Cited by 19
“The protein pathways have also been reproduced by others [1].”
BackgroundKerry, R. G., Das, G., Golla, U., Rodríguez-Torres, M. D. P., Shin, H., & Patra, J. K. (2020) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201021666201013153142 · Cited by 20
Martins‐de‐Souza, D., Carvalho, P. C., Schmitt, A., Junqueira, M., Nogueira, F. C. S., Turck, C. W., & Domont, G. B. (2013) · Journal of Proteome Research · doi:10.1021/pr4009157 · Cited by 16
Self-citationTurvey, M. E., Koudelka, T., Comerford, I., Greer, J. M., Carroll, W. M., Bernard, C. C. A., Hoffmann, P., & McColl, S. R. (2014) · Journal of Proteome Research · doi:10.1021/pr500158r · Cited by 20
Bamm, V. V., Geist, A. M., & Harauz, G. (2016) · Metabolic Brain Disease · doi:10.1007/s11011-016-9923-x · Cited by 14
What Have Advances in Transcriptomic Technologies Taught us About Human White Matter Pathologies?
Jäkel, S., & Williams, A. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00238 · Cited by 13
Dadashkhan, S., Mirmotalebisohi, S. A., Poursheykhi, H., Sameni, M., Ghani, S., Abbasi, M., Kalantari, S., & Zali, H. (2023) · Journal of Proteomics · doi:10.1016/j.jprot.2023.104890 · Cited by 15
Neuroproteomic profiling of human body fluids
Månberg, A., Schwenk, J. M., & Nilsson, P. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201500065 · Cited by 12
“summarizes the proteomic efforts performed during the last decade to study protein levels related to MS [70].”
BackgroundRamos, I., Lyng, F. M., Rehman, I. U., Sharrack, B., & Woodroofe, M. N. (2017) · Applied Spectroscopy Reviews · doi:10.1080/05704928.2017.1336450 · Cited by 10
“blood, cerebrospinal fluid (CSF) and urine rather than in MS CNS tissue (26, 27).”
Raphael, I., Mahesula, S., Purkar, A. B., Black, D. M., Catala, A., Gelfond, J. A. L., Forsthuber, T. G., & Haskins, W. E. (2014) · Scientific Reports · doi:10.1038/srep06210 · Cited by 9
Partridge, M. A., Myers, S. J., Gopinath, S., & Coorssen, J. R. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400141 · Cited by 8
“Notably, many proteins identified in these studies have also been found in the CSF of MS patients, including annexin A3, apolipoprotein E and Glial fibrillary acidic protein (reviewed in [24]).”
BackgroundHow can proteomics elucidate the complexity of multiple sclerosis?
Farias, A. S., & dos Santos, L. M. B. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400171 · Cited by 8
“Recently, we reviewed the last 10 years of proteomics studies in multiple sclerosis or EAE [38].”
BackgroundResultInfluentialSelf-citationA role for vessel‐associated extracellular matrix proteins in multiple sclerosis pathology
Pisa, M., Watson, J. L., Spencer, J. I., Niblett, G., Mahjoub, Y., Lockhart, A., Yates, R. L., Yee, S. A., Hadley, G., Ruiz, J. A., et al. (2024) · Brain Pathology · doi:10.1111/bpa.13263 · Cited by 4
“Previous proteomic study in people with MS has implicated a growing number of protein candidates that could serve as potential disease-specific markers amenable to targeted therapies [42 – 47].”
Ménoret, A., Crocker, S. J., Rodríguez, A., Rathinam, V. A. K., Clark, R. B., & Vella, A. T. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201500029 · Cited by 5
“-Enolase C CHF Cardiomyocytes 2D gel and MS [205] N EAE Spinal cord 2DE and MALDI-TOF MS [32] Multiple sclerosis CSF 2D-DIGE, MALDI-TOF MS and UPLC/Q-TOF MS [9]”
BackgroundMethodAI-Driven Precision Medicine and Personalized Healthcare for Immunological Disorders
Poovathanathil, S. A., Barage, S. H., & Singh, R. (2025) · Advances in computational intelligence and robotics book series · doi:10.4018/979-8-3693-9725-1.ch007 · Cited by 4
Identification of protein–protein interaction bridges for multiple sclerosis
Yazıcı, G., Vatandaşlar, B. K., Cantürk, İ. A., Aydınlı, F. İ., Düz, Ö. A., Karakoç, E., Kerman, B. E., & Alkan, C. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad175 · Cited by 2
“Farias et al. (2014) reported that ALDOA and APOE genes are up-regulated in CSF of MS patients.”
Mattioli, L., Stella, R., Peggion, C., Cagnin, S., Pifferi, A., Miraldi, E., Cappellucci, G., Baini, G., Camarda, L., Budriesi, R., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083350 · Cited by 1
“…enables comprehensive, unbiased profiling of protein expression in complex biological samples, capable of identifying and quantifying thousands of proteins in a single run, thereby revealing treatment-induced changes linked to OS, inflammation, neuronal survival, and synaptic plasticity [13–18].”
Deciphering the biochemistry and identifying biomarkers to multiple sclerosis
Martins‐de‐Souza, D., & Farias, A. S. (2015) · PROTEOMICS · doi:10.1002/pmic.201500332 · Cited by 1
“Important molecular leads for multiple sclerosis have been provided by proteomic studies of CNS [2].”
BackgroundSelf-citationPloumakis, A., Weiner, H. L., & Patsopoulos, N. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801496-7.00016-2 · Cited by 1
Loureiro, R., Vieira, M., Paulo, F., & Martins, C. (2017) · Revista Internacional de Acupuntura · doi:10.1016/j.acu.2017.01.001
Investigation of the adaptive immune response in multiple sclerosis
Rathbone, E. J. (2018) · University of Birmingham Institutional Research Archive (University of Birmingham)
The Role of MERTK in Central Inflammatory Demyelination
Dwyer, C. (2020) · Minerva Access (University of Melbourne)
Other omics approaches to the study of rare diseases
Gatta, G. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820140-4.00008-9
Liquid Chromatography Mass Spectrometry to the Study of Plasma Biomarkers in Multiple SclerosisPreprint
Yang, W., Wu, S., Sun, B.-Y., Zhang, L., Yan, X., Zhou, H., Li, H., Li, H., Fan, J., He, P., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1309240/v1
Zabihi, M. R., Moradi, Z., Salehi, Z., & Kavousi, K. (2025) · Discover Applied Sciences · doi:10.1007/s42452-025-07346-x
“In a study utilizing proteomics techniques on biological samples of MS, upregulation of CRKL was reported in blood samples [67]. miR-126 can be regarded as a negative regulator of CRKL at mRNA levels [68].”
Metadata
- Authors
- Farias, A. S., Pradella, F., Schmitt, A., Santos, L. M. B., & Martins‐de‐Souza, D.
- Affiliations
- Universidade Estadual de Campinas (UNICAMP) (BR)
- Universidade de São Paulo (BR)
- Corresponding author
- Farias, Alessandro S.
- ORCID
- Venue
- PROTEOMICS
- Publisher
- Wiley
- Published
- 2014-03
- Volume
- 14
- Issue
- 4-5
- Pages
- 467-480
- ISSN
- 1615-9853 (ISSN-L)
- 1615-9861
- OpenAlex
- W2117929821
- Cited by
- 40
- References
- 116
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 3 · 2020: 4 · 2019: 3 · 2018: 1 · 2017: 3 · 2016: 4 · 2015: 6 · 2014: 7
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- PROTEOMICS (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced Biosensing Techniques and Applications
- Keywords
- multiple sclerosis, biomarkers, demyelination, neurodegeneration, cerebrospinal fluid, blood-based biomarkers, disease mechanisms, treatment goals, central nervous system tissue
- MeSH terms
- Axons, Encephalomyelitis, Autoimmune, Experimental, Humans, Multiple Sclerosis, Biomarkers, Proteomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.